Oculis to Participate in Upcoming June Investor Conferences
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a…
21,360$
-0,84%
Echtzeit-Aktienkurs Oculis Holding AG
Bid:
Ask:
Nachrichten zur Oculis Holding AG Aktie
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -50.98% and 42.15%, respectively, for the quarter ended March 2025.…
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline
Oculis Holding AG (OCS) doesnt possess the right combination of the two key ingredients for a likely earnings beat in…
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a…
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a…
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or…
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or…
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the…
Oculis Publishes Notification of Major Changes in Voting Rights
ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights,…
Oculis to Present at the Stifel 2024 Healthcare Conference
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company…
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the…
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company…
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company…
Oculis Reports Q2 Financial Results and Provides Recent Company Update
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or…
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the…
Oculis and EURETINA Announces the Ramin Tadayoni Award
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the…
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the…
Oculis updates share capital for its existing at-the-market offering program
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”),…
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the…
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
ZUG, Switzerland, April 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the…
Oculis to Participate at Upcoming April Investor Conferences
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global…
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
ZUG, Switzerland and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the…